Epithelial-mesenchymal Transition and Its Regulators Are Major Targets of Triple-negative Breast Cancer

Overview

Journal Cell Adh Migr

Specialty Cell Biology

Date 2013 Oct 25

PMID 24152786

Citations 15

Authors

Ala-Eddin Al Moustafa

Affiliations

Soon will be listed here.

Abstract

Triple negative breast cancers (TNBCs) represent a distinct subtype of breast cancers that are associated with early recurrence and an aggressive metastatic progression of the disease and consequently poor outcome. Recently, it was reported that c-Met growth factor receptor is overexpressed in around 52% of TNBCs. On the other hand, it is known that c-Met signaling pathways initiate the epithelial-mesenchymal transition (EMT) phenomenon, which is described as a crucial event during cancer metastasis. Herein, we discuss the association between c-Met and EMT in the TNBC group.

Citing Articles

Role of Leptin and Adiponectin in Carcinogenesis.

Bocian-Jastrzebska A, Malczewska-Herman A, Kos-Kudla B Cancers (Basel). 2023; 15(17).

PMID: 37686525 PMC: 10486522. DOI: 10.3390/cancers15174250.

High level of FHL2 exacerbates the outcome of non-small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells.

Li N, Xu L, Zhang J, Liu Y Int J Exp Pathol. 2022; 103(3):90-101.

PMID: 35366027 PMC: 9107608. DOI: 10.1111/iep.12436.

Antitumorigenic Effect of Tramadol and Synergistic Effect With Doxorubicin in Human Breast Cancer Cells.

Huang Y, Sue S, Wu Z, Huang S, Lee S, Wu Z Front Oncol. 2022; 12:811716.

PMID: 35155248 PMC: 8826738. DOI: 10.3389/fonc.2022.811716.

Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET.

Huang W, Yen J, Sung Y, Tung S, Chen P, Chu P Oncogene. 2022; 41(7):997-1010.

PMID: 34974522 PMC: 8837547. DOI: 10.1038/s41388-021-02136-2.

Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.

Kashyap A, Umar S, Dev J R A, Prasad C Asian Pac J Cancer Prev. 2021; 22(7):2177-2184.

PMID: 34319041 PMC: 8607078. DOI: 10.31557/APJCP.2021.22.7.2177.

References

Lengyel E, Prechtel D, Resau J, Gauger K, Welk A, Lindemann K . C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2004; 113(4):678-82. DOI: 10.1002/ijc.20598. View

Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V . Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem. 2004; 279(19):19908-15. DOI: 10.1074/jbc.M313191200. View

Zagouri F, Bago-Horvath Z, Rossler F, Brandstetter A, Bartsch R, Papadimitriou C . High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer. 2013; 108(5):1100-5. PMC: 3619063. DOI: 10.1038/bjc.2013.31. View

Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J . c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology. 2000; 36(4):313-25. DOI: 10.1046/j.1365-2559.2000.00847.x. View

Yan D, Avtanski D, Saxena N, Sharma D . Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem. 2012; 287(11):8598-612. PMC: 3318705. DOI: 10.1074/jbc.M111.322800. View

Law J, Habibi G, Hu K, Masoudi H, Wang M, Stratford A . Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008; 68(24):10238-46. DOI: 10.1158/0008-5472.CAN-08-2755. View

Cirillo D, Rachiglio A, La Montagna R, Giordano A, Normanno N . Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008; 105(4):956-64. DOI: 10.1002/jcb.21911. View

Otvos Jr L, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A . Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011; 47(10):1578-84. DOI: 10.1016/j.ejca.2011.01.018. View

Spina A, Di Maiolo F, Esposito A, DAuria R, Di Gesto D, Chiosi E . Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells. Front Biosci (Landmark Ed). 2013; 18(1):133-44. DOI: 10.2741/4092. View

10.

Sivakumar R, Koga H, Selvendiran K, Maeyama M, Ueno T, Sata M . Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. Int J Oncol. 2009; 34(2):329-38. View

11.

Hung C, Kuo D, Chou C, Su Y, Ho C, Way T . Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells. J Agric Food Chem. 2011; 59(17):9683-90. DOI: 10.1021/jf2021489. View

12.

Guarino M . Src signaling in cancer invasion. J Cell Physiol. 2010; 223(1):14-26. DOI: 10.1002/jcp.22011. View

13.

Hursting S, Lavigne J, Berrigan D, Perkins S, Barrett J . Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med. 2003; 54:131-52. DOI: 10.1146/annurev.med.54.101601.152156. View

14.

Davis A, Kaklamani V . Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer. 2012; 2012:809291. PMC: 3262602. DOI: 10.1155/2012/809291. View

15.

Moustafa A, Achkhar A, Yasmeen A . EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Front Biosci (Schol Ed). 2011; 4(2):671-84. DOI: 10.2741/s292. View

16.

Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I . TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 2011; 30(4):783-95. PMC: 3041949. DOI: 10.1038/emboj.2010.351. View

17.

Ocal I, Dolled-Filhart M, DAquila T, Camp R, Rimm D . Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003; 97(8):1841-8. DOI: 10.1002/cncr.11335. View

18.

Rock C, Pande C, Flatt S, Ying C, Pakiz B, Parker B . Favorable changes in serum estrogens and other biologic factors after weight loss in breast cancer survivors who are overweight or obese. Clin Breast Cancer. 2013; 13(3):188-95. PMC: 4153749. DOI: 10.1016/j.clbc.2012.12.002. View